Qiu Sufang, Lu Jun, Zheng Wei, Xu Luying, Lin Shaojun, Huang Chaobin, Xu Yuanji, Huang Lingling, Pan Jianji
Department of Radiation Oncology, Fujian Provincial Cancer Hospital, Provincial Clinical College of Fujian Medical University, Fuzhou, Fujian, People's Republic of China.
BMC Cancer. 2014 Nov 3;14:797. doi: 10.1186/1471-2407-14-797.
Recurrent T1-2 Nasopharyngeal Carcinoma (rT1-2) may be salvaged by 3D - CRT (3D-Conformal Radiotherapy), IMRT (Intensity Modulated Radiotherapy), Brachytherapy (BT), BT with external radiotherapy. The purpose of this study is to address the efficacy and toxicity profile of aforementioned four modalities for rT1-2 NPC.
168 patients, median age 48 years (range 16-75 years) proven rT1-2 NPC were diagnosed and treated with four different irradiation modalities (3D-CRT, IMRT, BT, BT with external radiotherapy). Median time to recurrence was 30 months (range 1-180 months). The median follow-up time was 28 months (range, 4-135 months).
161 patients completed a median dose of 6445 cGy (ranging 30 to 87 Gy). Seven patients prematurely terminated their treatment due to acute side-effects and received 30-49 Gy. The 1- and 3-year local regional recurrent free survival (LRRFS), distant free survival (DFS), and overall survival (OS) rates were 82.03% vs. 82.03% vs. 82.58%, 51.33% vs. 51.33% vs. 53.41, respectively. Gender and recurrence T-classification were the two significant adverse prognostic factors for LRRFS, DFS, and OS rates. Grade 3 or 4 toxicities were tolerable.
3D-CRT, IMRT, BT, BT with external radiotherapy are feasible and efficacious for rT1-2 NPC. In toxicity 3D-CRT/IMRT group is lower than BT group. IMRT is superior for rT1-2 NPC.
复发性T1-2期鼻咽癌(rT1-2)可通过三维适形放疗(3D-CRT)、调强放疗(IMRT)、近距离放疗(BT)、近距离放疗联合外照射放疗进行挽救性治疗。本研究旨在探讨上述四种治疗方式对rT1-2期鼻咽癌的疗效和毒性特征。
168例确诊为rT1-2期鼻咽癌的患者,中位年龄48岁(范围16-75岁),接受了四种不同的放疗方式(3D-CRT、IMRT、BT、BT联合外照射放疗)治疗。复发的中位时间为30个月(范围1-180个月)。中位随访时间为28个月(范围4-135个月)。
161例患者完成了中位剂量为6445 cGy(范围30-87 Gy)的治疗。7例患者因急性副作用提前终止治疗,接受了30-49 Gy的剂量。1年和3年的局部区域无复发生存率(LRRFS)、远处无复发生存率(DFS)和总生存率(OS)分别为82.03%对82.03%对82.58%,51.33%对51.33%对53.41%。性别和复发T分期是影响LRRFS、DFS和OS率的两个显著不良预后因素。3级或4级毒性是可耐受的。
3D-CRT、IMRT、BT、BT联合外照射放疗对rT1-2期鼻咽癌是可行且有效的。在毒性方面,3D-CRT/IMRT组低于BT组。IMRT对rT1-2期鼻咽癌更具优势。